logo

For the Inventor, By the Inventor

Yokohama, Japan

Toshiji Kanayama

This inventor holds 11 USPTO granted patents. Top assignees: Mitsubishi Yuka Pharmaceutical Co., Ltd., Sagami Chemical Research Center, Mitsubishi Chemical Industries Limited. Active years: 1980-2001.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Toshiji Kanayama. Retrieved from https://idiyas.com/inventor/toshiji-kanayama

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 11

% Patents Active = 100.0

Average Co-Inventor Count = 5.3

ph-index = 4

Forward Citations = 62(Granted Patents)


Location History:

  • Amimachi, JP (1982)
  • Ibaraki, JP (1989)
  • Ami, JP (1980 - 1991)
  • Kanagawa, JP (1995)
  • Yokohama, JP (1992 - 2001)

Company Filing History:

goldMedal4 out of 13 
 
Mitsubishi Yuka Pharmaceutical Co., Ltd.
 patents
silverMedal3 out of 191 
 
Sagami Chemical Research Center
 patents
bronzeMedal2 out of 614 
 
Mitsubishi Chemical Industries Limited
 patents
4. 2 out of 499 
 
Mitsubishi Kasei Corporation
 patents
5. 2 out of 546 
 
Mitsubishi Petrochemical Company Limited
 patents
6. 2 out of 1,040 
 
Shiseido Company, Limited
 patents
7. 1 out of 2,423 
 
Mitsubishi Chemical Corporation
 patents
where one patent can have more than one assignee

Years Active: 1980-2001

Loading Chart...
11 patents (USPTO):Explore Patents
1. 6174543 - Antidiabetic external skin application composition (2001-01-16),
2. 5798389 - Glomerulonephritis inhibitor (1998-08-25),
3. 5462941 - 3,6-disubstituted pyradazine derivatives (1995-10-31),
4. 5089494 - 4-phenylphthalazine derivatives which inhibit platelet aggregation (1992-02-18),
5. 5053526 - Pharmaceuticals containing prostaglandin I.sub.2 (1991-10-01),
6. 4839388 - Prostacyclins and pharmaceuticals containing the same (1989-06-13),
7. 4699921 - Pharmaceuticals containing prostaglandin I.sub.2 (1987-10-13),
8. 4668677 - 4-phenylphthalazine derivatives, their preparation and their use as (1987-05-26),
9. 4352928 - 5,6-Alkylenepyrimidine derivative (1982-10-05),
10. 4330533 - Novel polysaccharide and hypocholesterol composition containing the same (1982-05-18),
11. 4230800 - Process for producing a polysaccharide using Pseudomonas (1980-10-28),

Title: The Innovations of Toshiji Kanayama

Introduction

Toshiji Kanayama is a prominent inventor based in Yokohama, Japan. He has made significant contributions to the field of pharmaceuticals, particularly in the development of innovative medical compositions. With a total of 11 patents to his name, Kanayama's work has had a notable impact on healthcare.

Latest Patents

Among his latest patents is an antidiabetic external skin application composition. This composition contains glibenclamide and benzyl alcohol, and optionally a nonionic surfactant. Another significant patent is for a glomerulonephritis inhibitor, which is a medicine effective in inhibiting glomerulonephritis. This inhibitor contains docosahexaenoic acid or a salt, ester, or amide thereof, or other derivatives of docosahexaenoic acid.

Career Highlights

Throughout his career, Kanayama has worked with notable companies such as Mitsubishi Yuka Pharmaceutical Co., Ltd. and Sagami Chemical Research Center. His experience in these organizations has allowed him to develop groundbreaking medical solutions that address critical health issues.

Collaborations

Kanayama has collaborated with esteemed colleagues, including Katsuhiko Iseki and Motokuni Mori. These partnerships have fostered an environment of innovation and creativity, leading to the development of effective medical treatments.

Conclusion

Toshiji Kanayama's contributions to the field of pharmaceuticals through his patents and collaborations highlight his dedication to improving healthcare. His innovative spirit continues to inspire advancements in medical science.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…